Opthea Ltd has released a press release.
Opthea Completes FDA Meeting to Inform OPT-302 Program
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Opthea
- Opthea Completes Patient Enrolment in Ph1/2A wAMD Trial
- Opthea receives $2.6M R&D tax incentive
- Appendix 4E and Annual Report 2016
- Opthea reports positive data from Phase 1 wet AMD Trial
- Opthea Doses First Patient in Ph2A for OPT-302 in Wet AMD
Later from Opthea
- Opthea Receives EU Regulatory Feedback for OPT-302 Program
- Opthea Launches A$45M Financing for Clinical Development
- Opthea Successfully Completes Institutional Capital Raising
- Opthea Completes A$45 Million Capital Raising
- Opthea Allowed Key Patent for OPT-302 in United States
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea